GCC Fabry disease access is infrastructure-gated, not formulary-gated: both ERT and oral therapy are covered, yet diagnosis in women lags.

Fabry disease prevalence in GCC males is estimated at 1 in 20,000 to 30,000 versus roughly 1 in 40,000 globally, with specific Arabian Peninsula founder mutations documented at KFSH&RC that create family clusters of 4 to 8 affected males across 2 to 3 GCC generations. Total diagnosed Fabry patients across the GCC number approximately 200 to 300, but true prevalence is likely 3 to 5 times higher given the diagnostic gap, especially in heterozygous females. GCC male patients present with more advanced renal involvement at diagnosis than European cohorts, a median GFR of 45 to 55 mL/min versus 65 to 75 mL/min in Europe.

Heterozygous female Fabry disease, which causes significant morbidity including GFR decline, white matter lesions, and cardiomyopathy despite X-linked inheritance, is systematically under-identified across the GCC: women rarely undergo cascade screening after a male family member's diagnosis. Estimated female Fabry patients run 2 to 3 times the male burden, yet diagnosed female cases represent fewer than half the male diagnosis rate. Both enzyme replacement therapy (agalsidase beta) and oral chaperone therapy (migalastat, for amenable mutations) are NPHC-covered, but migalastat uptake is constrained by HEK cell assay availability limited to KFSH&RC alone.

Women carry most of the undiagnosed Fabry disease burden in the GCC.

Five questions this report answers:

Q1 - How many GCC Fabry patients remain undiagnosed once corrected for the female screening gap?

Q2 - Why do GCC male Fabry patients present with more advanced renal disease than European cohorts?

Q3 - What does the single HEK assay bottleneck mean for migalastat uptake against ERT?

Q4 - What diagnostic and access barriers define the addressable GCC Fabry disease market?

Q5 - Why does GCC Fabry disease access depend on infrastructure rather than formulary coverage?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#FabryDisease #RareDisease #LysosomalStorageDisorder #GCCHealthcare #DiseaseLandscape

Live report page:  https://axlrx.ai/fabry-disease/gcc/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-           hello@axlrx.ai

Web-           https://axlrx.ai/